BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home » Blogs » BioWorld MedTech Perspectives

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Faster results from diagnostics could reduce anxiety

July 26, 2013
By Omar Ford
How many of us have ever gone into the doctor to undergo some tests and then have to wait several days to get the results? Is it just me or can the wait be a bit maddening? I mean in all that time, the thoughts that can run through your head are overwhelming right? In a society where things are increasingly speeding up, it's incredible that there isn't a stronger push for making patients aware of their test results much earlier. One med-tech company is focused on developing tests that could garner rapid results for patients, and quite possibly eliminate...
Read More

Meaningless use; the current state of healthcare IT

July 22, 2013
By Mark McCarty
It’s tempting to amuse oneself about healthcare IT by juxtaposing it with a more or less dusty fixture of pop culture. For instance, you can sing the Bob Seger song “Beautiful loser,” and substitute the words “meaningful user” to parody things, but there are huge problems with healthcare IT, and they’re not particularly funny. For instance, the head honcho at the Office of the National Coordinator appeared on Capitol Hill last week and gave the Senate Finance Committee a glowing report on healthcare IT adoption. However,...
Read More

Telomerase; miracle medicine or just more cost?

July 18, 2013
By Mark McCarty
As is the case with many other areas of the modern world, medical science has made enormous strides over the past century or so, and it seems as though the pace of change is accelerating. It’s like being with Edwin Hubble and Georges Lemaître when they first started looking at far-flung regions of the universe. They both realized the universe was expanding, but what was not immediately obvious was that the expansion was accelerating. To me, that’s where things stand with medical science now, and while the chatter about telomerase has...
Read More

Beltway Blues: The device tax, the ACA, and a cheap antidepressant

July 11, 2013
By Mark McCarty
Paying too much attention to something can be depressing if you’re hoping for change in a particular direction, so device makers might be forgiven for ignoring the goings-on inside I-495, that vaguely circular slab of pavement running ‘round our nation’s capital. So is there any cause for med tech optimism about inside-the-Beltway developments? I’ll just say that you might want to indulge more frequently in a time-tested mood elevator this summer, one that requires no prescription. Device tax repeal in limbo Device tax repeal legislation is...
Read More

A journey through Ontario's life sciences

July 9, 2013
By Amanda Pedersen
  Writing about medical devices on a daily basis without ever seeing the inside of a life sciences laboratory or a healthcare facility would be a bit like a sports writer who never steps foot inside a stadium. And yet many of us journalists rarely get the opportunity to see where all the magic happens in the industries we cover so faithfully. Recently I had an opportunity, for the second time, to visit nearly a dozen life...
Read More

I've got 99 problems but a CT scan isn't one of 'em

June 28, 2013
By Omar Ford
As a proud father of a two-year-old little girl, it's always stories the stories about children that grab my attention the most. Take for instance, a recent one that I wrote, discussing the risk of radiation-induced solid cancers in older children. The story comes from a study published in the journal JAMA Pediatrics and possible appendicitis was cited as a leading cause of abdominal/pelvic CT usage. The first question I asked myself, one that I had never asked before... was if I should be overly concerned if my daughter needs a CT scan. The good news is, one med-tech company...
Read More

Double trouble: Two firms under FDA’s microscope

June 28, 2013
By Mark McCarty
A lot of warning letters and other FDA enforcement action are addressed to obscure companies, but lately a few big names have come under scrutiny. In a recent posting here at MDD Perspectives, we addressed a warning letter to Edwards Lifesciences, but they’re not the only big name to show up behind the FDA woodshed. Is this a trend or mere chance? I’ll let you decide. FDA recently posted the 483 from an inspection of Intuitive Surgical of Sunnyvale, California, which is not unheard of, but is not...
Read More

The Supreme Court speaks: Is the Myriad story over?

June 19, 2013
By Mark McCarty
The Supreme Court finally published its decision in the case of Association for Molecular Pathology v. Myriad Genetics, a case that seemed to hover over the landscape of life science patents for an eternity. We might be tempted to think the decision shuts the door on a very contentious area of patent law. After all, we now know isolated DNA is not patentable, but complementary DNA is. So that’s it, right? Wrong. In fact, at least one observer believes the decision may collapse at some point. Richard Gilly...
Read More

Life science confidential? Not lately

June 13, 2013
By Mark McCarty
We all know there’s no such thing as a free lunch, but what’s not always clear is the cost. The U.S. federal government in two of its incarnations recently put those in the life science industries on alert that the cost of doing business might go up to a degree that may surprise anyone who hasn’t been paying attention. FDA proposed recently to make freely available “de-identified and masked data derived from medical product applications,” citing as a “national priority” the need to improve “the efficiency and effectiveness of...
Read More

Getting in at the ground floor no longer viable for VCs

June 7, 2013
By Omar Ford
In a recent conversation with one of my good friends who has been in the music industry off and on for 20+ years, I realized that there are some glaring similarities between that form of entertainment and med-tech. Consider this quote from my friend if you will: "Nowadays Omar, you have to create a buzz around yourself. You have to get people's attention and do most of the leg work yourself before a major label (distributor) will even look at you, or invest in you." When he said this, I began thinking about how difficult it was to get funding...
Read More
Previous 1 2 … 27 28 29 30 31 32 33 34 35 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing